Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD CSJ117 - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04410523 (CCSJ117A12201C) Asthma Phase 2 625 Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment. Average change from baseline in pre-dose FEV1 at week 8 & week 12 CSJ117 0.5mg CSJ117 1mg CSJ117 2 mg CSJ117 4 mg CSJ117 8 mg Placebo Asthma patients on background medium or high ICS plus LABA therapy Target Patients Read-out Milesstone(s) Publication 2022 Primary publications planned for 2022 102 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation